mgc pharma

First CannEpil™ Product arrives in Australia

- In a significant milestone event for the Company, the first shipment of CannEpil™ was officially exported from Slovenia on Friday to arrive in Australia today, Monday 24 December

- All Australian import authorisations are in place to allow immediate transport to a secure facility at St Vincent's Hospital, Melbourne

- CannEpil™ is available for supply through Authorised Prescribers, endorsed by the Human Research Ethics Committee at St Vincent's Hospital

- CannEpil™ is a Cannabinoids based IMP Phytomedicine developed by MXC

- Some Australian medical practitioners have already been granted approval as Authorised Prescribers of CannEpil™

- MXC and specialist pharmaceutical distributor, HL Pharma, are now able to arrange the supply of CannEpil™ for patients who have been prescribed the product by an Authorised Prescriber

MGC Pharmaceuticals Ltd (ASX: MXC or "the Company") is pleased to announce that its first investigational medicinal product (IMP) **CannEpil™** has been successfully exported from Slovenia and imported into Australia today for the first time, after completing the validation process. The Company's first batch of CannEpil™ will arrive in Australia today after being air freighted from Slovenia over the weekend.

MXC manufactures high quality products in accordance with European GMP standards. CannEpil™ is a Cannabinoids based IMP Phytomedicine developed by MXC.

MXC and HL Pharma will work together to arrange for the supply of CannEpil™ in Australia to eligible Authorised Prescribers.

Authorised Prescribers may prescribe CannEpil™ to suitable patients under their care.

Some of the Authorised Prescribers of CannEpil™ were first endorsed by the Human Research Ethics Committee at St Vincent's Hospital, Melbourne.

ASX RELEASE

The arrival of CannEpil™ into Australia for the first time represents a significant milestone for the Company and its development as an accomplished European-based biopharma company with more than a decade of clinical experience and a leading Board of scientific advisors.

Who is an Authorised Prescriber?
An Authorised Prescriber is a medical practitioner who has been authorised to prescribe a medicine which has not otherwise been approved for use in Australia by the Therapeutic Goods Administration (**TGA**). In order to obtain authorisation to be an Authorised Prescriber, a medical practitioner must obtain endorsement from an Ethics Committee, which requires the medical practitioner seeking to become an Authorised Prescriber to demonstrate the safety of the medicine and their expertise to prescribe it.

The Company continues to focus on research, development and production of further medicinal cannabis-based products to bring them to market in Australia and internationally.

Roby Zomer, Co-founder and Managing Director, MGC Pharmaceuticals commented

"The arrival of CannEpil in Australia is a great achievement for us on our pathway to growing and commercialising MXC as a European-based biopharma company. The team has been working extremely hard to get to this stage and we are all very excited that CannEpil is now available for supply to patients in Australia, which is the first key market for the Company to deliver CannEpil into with more to follow during 2019."

--Ends—

For further information, please contact:

Media Enquiries	**MGC Pharmaceuticals Ltd**
Justin Kelly	Brett Mitchell
Media and Capital Partners	Executive Chairman
+61 408 215 858	+61 8 6382 3390
Justin.kelly@mcpartners.com.au	info@mgcpharma.com.au

About MXC

MGC Pharmaceuticals Ltd (ASX: MXC) is an EU based bio-pharma company with many years of technical clinical and commercial experience in the medical cannabis industry. The Company's founders are key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality cannabinoid-based pharmaceutical products for the growing demand in the medical markets in Europe, North America and Australasia.

Follow us through our social media channels